MyOme Presents New Data on an Integrated Polygenic Risk Score to Improve Coronary Artery Disease Prediction at the American College of Medical Genetics and Genomics Annual Meeting
Integrated polygenic risk score can more accurately identify people at high risk of developing coronary artery disease across diverse ancestries over a commonly used clinical
“MyOme, Natera Show Cross-Ancestry Polygenic Risk Score Improves Breast Cancer Prediction”-GenomeWeb
From GenomeWeb: “NEW YORK – Personalized genomics company MyOme’s cross-ancestry, integrated risk score (caIRS) improved breast cancer prediction over the standard Tyrer-Cuzick (T-C) model in
MyOme Announces Publication of a Validated Cross-Ancestry Polygenic Risk Score for Breast Cancer
Data demonstrates improved breast cancer risk prediction across multiple ancestries over standard of care February 22, 2023, Menlo Park, CA. Myome, Inc., a clinical whole
MyOme Presents New Data at ASHG 2022 on an Ethnically-Inclusive Breast Cancer Risk Assessment
Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries MENLO
MyOme Secures $23M in Series B Funding to Deliver Clinical Whole Genome Insights to Help Families Manage Risk for Inherited Diseases
The oversubscribed series B financing led by Healthcare Venture Partners, added SoftBank Corp.and Natera to existing investors– Sequoia Capital, Foresite Capital, Founders Fund, among others
“Equity Issues, Admixed Populations Continue to Complicate Use of Polygenic Risk Scores” — GenomeWeb
“A dearth of genome-wide association studies focused on non-European populations, plus issues related to applying polygenic risk scores in populations with multiple ancestries, has spurred
“MyOme Develops Cross-Ancestry Breast Cancer Polygenic Risk Score, Plans Product Launch” — GenomeWeb
“NEW YORK – Personalized genomics company MyOme presented data at the recent American Society of Clinical Oncology conference demonstrating its ability to train and validate
MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast Cancer
MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast CancerStudy highlights potential of Polygenic Risk Scores (PRS) to improve breast
“Is it time to test embryos for common diseases?” — MedicalXpress.com
“A Silicon Valley company has designed a technique to decipher the genetic code of a tiny embryo and calculate its future risk of cancer, diabetes
“Scientists say they can read nearly the whole genome of an IVF-created embryo” — Science.org
“A California company says it can decipher almost all the DNA code of a days-old embryo created through in vitro fertilization (IVF)—a challenging feat because
